Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
Bert van Meurs, Chief Business Leader Image Guided Therapy and Member of the Executive Committee at Royal Philips, shared on LinkedIn:
”New late-breaking results from the iMODERN trial, presented at TCT 2025, bring important clarity for heart attack patients with multi-vessel disease.
This global study confirms that treating additional lesions during the initial procedure is just as safe as waiting to stage treatment, giving clinicians more flexibility to tailor care to each patient’s needs.
Complementary findings from the ILIAS ANOCA study also highlight the value of physiology-guided assessment and personalized therapy for patients with angina but no obstructive coronary arteries, resulting in sustained improvements in quality of life.
I’m proud that Philips solutions supported both of these impactful studies.
Together with our clinical partners, we’re helping advance evidence-based, individualized cardiovascular care for patients worldwide.”
Read the full announcement here.
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 13:53Steven Lubega: Why Are Healthy Newborns Born Poorly Equipped To Stop Bleeding?
-
Aug 11, 2026, 13:47Why Stroke Risk Changes During Pregnancy – International Journal of Stroke
-
Aug 11, 2026, 13:43Moyahabo Julius Rampya: Shaping the Future of Stroke Care in Africa
-
Aug 11, 2026, 13:34Brett Hoover: Plaque Burden May Be Key to Predicting MACE Risk
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC